BioCentury | Jul 6, 2020
Product Development

July 6 Quick Takes: Cellectis CAR T trial halted; plus data readouts from Bellus, ObsEva, Idorsia, and more

...receptor OX1R (HCRTR1) - Orexin 1 receptor OX2R (HCRTR2) - Orexin 2 receptor P2X3 - Purinergic receptor P2X...
BioCentury | Mar 19, 2020
Product Development

March 18 Quick Takes: Duo of Phase III data for Pfizer; plus Sage, Allergan-AbbVie, Merck, DermTech, Beijing Tide-Insilico

...to Partner with Insilico” ). Targets IL-23 - Interleukin-23 JAK-1 - Janus kinase-1 P2X3 - Purinergic receptor P2X...
...3 TERT - Telomerase reverse transcriptase BioCentury Staff Allergan Inc. AbbVie Inc. Merck & Co. Inc. Sage Therapeutics Inc. Pfizer Inc. Interleukin-23 (IL-23) Purinergic receptor P2X...
BioCentury | Sep 5, 2019
Financial News

Sept. 5 Financial Quick Takes: Zealand raises cash as it readies NDA; plus Bellus, Aerie, LNC, Veralox and Sigrid

...and at risk for Type II diabetes. Targets: ALOX12 (12-LOX) - Arachidonate 12-lipoxygenase; P2X3 - Purinergic receptor P2X...
BioCentury | Sep 4, 2019
Financial News

Sept. 4 Financial Quick Takes: BrightGene looks to STAR; plus IPO updates from Immunotech, 10x Genomics, SpringWorks, IGM, Satsuma and more

...that would give it a dual listing. The company's BLU-5937, a small molecule antagonist of purinergic receptor P2X...
BioCentury | Jun 20, 2019
Company News

Beyond Keytruda: Merck details plans for future growth

...a nucleotide reverse transcriptase inhibitor. A third program highlighted by Merck was gefapixant (MK-7264), a purinergic receptor P2X...
...succession timing, Merck said at the time. Targets: DPP-4 (CD26) - dipeptidyl peptidase-4; P2X3 - Purinergic receptor P2X...
BioCentury | May 28, 2019
Distillery Therapeutics

Inhibition of VEGF-A, P2RX7 or the combination of FLT1 and VEGFR-2 to treat tuberculosis

...RA). TARGET/MARKER/PATHWAY: Vascular endothelial growth factor A (VEGF-A); VEGF receptor 1 (FLT1; VEGFR-1); VEGFR-2 (KDR/Flk-1); purinergic receptor P2X...
...14, 2019 doi:10.1016/j.celrep.2019.04.072 CONTACT: Matyas Sandor, University of Wisconsin-Madison, Madison, Wis. email: msandor@wisc.edu Claire Quang University of Wisconsin-Madison Purinergic receptor P2X...
BioCentury | Apr 17, 2019
Emerging Company Profile

Nocion: Targeting pain neurons and nothing else

...compounds means they can only enter cells with large, open transient receptor potential (TRP) and purinergic receptor P2X...
BioCentury | Feb 5, 2019
Distillery Therapeutics

Neurology

...sclerosis (MS) and pain, and the P2RX7 antagonist AFC-5278 in preclinical testing for osteoporosis. TARGET/MARKER/PATHWAY: Purinergic receptor P2X...
...Jan. 25, 2019 doi:10.1523/JNEUROSCI.1895-18.2019 CONTACT: Beáta Sperlágh, Hungarian Academy of Sciences, Budapest, Hungary email: sperlagh@koki.hu Claire Quang Purinergic receptor P2X...
BioCentury | Sep 26, 2018
Distillery Techniques

Biomarkers

...Next steps could include validating the findings in larger cohorts of patients. DESCRIPTION: SNP on purinergic receptor P2X...
...CONTACT: Paolo Fiorina, Boston Children’s Hospital, Harvard Medical School, Boston, Mass. email: paolo.fiorina@childrens.harvard.edu Alicia Parker Harvard Medical School Purinergic receptor P2X...
BioCentury | Aug 16, 2018
Distillery Therapeutics

Neurology

...has the P2RX7 antagonist RQ-00466479 in preclinical testing for neuropathic pain. TARGET/MARKER/PATHWAY: Pannexin 1 (PANX1); purinergic receptor P2X...
...Trang, University of Calgary, Calgary, Alberta email: trangt@ucalgary.ca Claire Quang University of Calgary Integrin beta(2) (MAC-1) (CD18) Pannexin 1 (PANX1) Purinergic receptor P2X...
Items per page:
1 - 10 of 55